Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Fox

Showing results (161-170 of 182) with videos related to

Pageof 19
Sort By:
Trials|March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxisDavid I Dolling, Monica Desai, Alan McOwan, et al.
AIDS Care|August 15, 2019
Association of HIV status with sexual function in women aged 45-60 in England: results from two national surveysNasreen Toorabally, Catherine H Mercer, Kirstin R Mitchell, et al.
Nature Communications|October 30, 2022
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8<sup>+</sup> T cell immunityMiriam Rosás-Umbert, Jesper D Gunst, Marie H Pahus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
BMJ Open|March 17, 2023
Common health assets protocol: a mixed-methods, realist evaluation and economic appraisal of how community-led organisations (CLOs) impact on the health and well-being of people living in deprived areasRachel Mairi Baker, Mohasin Ahmed, Marcello Bertotti, et al.
Lancet (London, England)|February 23, 2020
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trialSarah Fidler, Wolfgang Stöhr, Matt Pace, et al.
Plos One|April 21, 2017
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP studyMitzy Gafos, Elizabeth Brodnicki, Monica Desai, et al.
Ebiomedicine|June 16, 2023
Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trialCarolina Herrera, Jennifer Serwanga, Laura Else, et al.
Nature Communications|January 31, 2026
Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trialLinos Vandekerckhove, Julie Fox, Borja Mora-Peris, et al.
AIDS (London, England)|June 8, 2023
A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskinCosnet L Rametse, Emily L Webb, Carolina Herrera, et al.
Pageof 19

Showing results (161-170 of 182) with videos related to

Sort By:
Pageof 19
Trials|March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxisDavid I Dolling, Monica Desai, Alan McOwan, et al.
AIDS Care|August 15, 2019
Association of HIV status with sexual function in women aged 45-60 in England: results from two national surveysNasreen Toorabally, Catherine H Mercer, Kirstin R Mitchell, et al.
Nature Communications|October 30, 2022
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8<sup>+</sup> T cell immunityMiriam Rosás-Umbert, Jesper D Gunst, Marie H Pahus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
BMJ Open|March 17, 2023
Common health assets protocol: a mixed-methods, realist evaluation and economic appraisal of how community-led organisations (CLOs) impact on the health and well-being of people living in deprived areasRachel Mairi Baker, Mohasin Ahmed, Marcello Bertotti, et al.
Lancet (London, England)|February 23, 2020
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trialSarah Fidler, Wolfgang Stöhr, Matt Pace, et al.
Plos One|April 21, 2017
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP studyMitzy Gafos, Elizabeth Brodnicki, Monica Desai, et al.
Ebiomedicine|June 16, 2023
Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trialCarolina Herrera, Jennifer Serwanga, Laura Else, et al.
Nature Communications|January 31, 2026
Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trialLinos Vandekerckhove, Julie Fox, Borja Mora-Peris, et al.
AIDS (London, England)|June 8, 2023
A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskinCosnet L Rametse, Emily L Webb, Carolina Herrera, et al.
Pageof 19